| Trial ID # | NCT03319628 |
| Phase | Ib/II |
| Drug Class | Antibody Drug Conjugates: NaPi2b |
| Drug Name | Upifitamab rilsodotin |
| Alternate Drug Names | XMT-1536, UpRi |
| Drugs in Trial | Upifitamab rilsodotin |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 97; 90% Pt-R; 70% w/ prior Bev; 59% w/ prior PARP inhibitor |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, evaluated per RECIST |
| Efficacy | All treatment doses (n=75): Dose group 36 (33-38 mg/m2) (n=25): Dose group 43 (38-43 mg/m2)(n=48): Exploratory analysis, NaPi2b High, TPS≥75: |
| Clinically Significant Adverse Events | Dose group 43 vs Dose group 36: |
| Conclusion | UpRi (XMT-1536) is well tolerated and shows promising signs of anti-tumor activity in platinum resistant ovarian cancer; UpRi at the 36mg/m2 dose demonstrates robust clinical activity with a differentiated safety profile |
| Reference | Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update, press release, 11/9/21 Slide from company update, Nov 2021 Slide from SGO 2022 presentation, Scientific Plenary III, abstract 228 |